Navigation Links
XTL Biopharmaceuticals Announces Completion of Patient Randomization Into the Bicifadine Phase 2b Clinical Trial for the Treatment of Diabetic Neuropathic Pain
Date:6/30/2008

11-point Pain Intensity Numeric Rating Scale (formerly referred to as the LIKERT scale).

Bicifadine is being developed for the treatment of diabetic neuropathic pain which represents a significant unmet medical need in the rapidly growing multi-billion dollar neuropathic pain market. Bicifadine is a member of the SNRI drug class, a proven class in the treatment of diabetic neuropathic pain. Bicifadine's efficacy in reducing pain has been demonstrated in over 15 clinical trials in acute pain, and its safety profile has been established in over 3,000 patients. Importantly, Bicifadine has a unique ratio of reuptake inhibition of serotonin versus norepinephrine, which differentiates it from other members of the SNRI drug class.

Ron Bentsur, XTL's Chief Executive Officer, commented, "We are very excited to have completed this milestone of patient randomization ahead of our projected timeline, and we remain grateful for the tremendous dedication of the investigators who are participating in the study." Mr. Bentsur added, "We eagerly await the outcome of this study in Q4 2008."

XTL in-licensed the world-wide rights to Bicifadine from Dov Pharmaceutical, Inc. (NASDAQ OTC: DOVP) in January 2007.

ABOUT XTL BIOPHARMACEUTICALS LTD.

XTL Biopharmaceuticals Ltd. ("XTL") is engaged in the development of therapeutics for the treatment of diabetic neuropathic pain and HCV. XTL is developing Bicifadine, a serotonin and norepinephrine reuptake inhibitor, for the treatment of diabetic neuropathic pain, which is currently in a Phase 2b study. XTL has out-licensed its novel pre-clinical HCV small molecule inhibitor program. XTL also has an active in-licensing and acquisition program designed to identify and acquire additional drug candidates. XTL is publicly traded on the NASDAQ and Tel-Aviv Stock Exchanges (NASDAQ:

SOURCE XTL Biopharmaceuticals Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Morria Biopharmaceuticals Plc Announces the Initiation of a Phase II Clinical Multi-dose Study of MRX-4 in Allergic Rhinitis
2. Morria Biopharmaceuticals Plc Announces Regulatory Approval to Commence Phase II Clinical Study of MRX-4 in Allergic Rhinitis
3. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
4. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
5. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
6. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
7. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
8. Morria Biopharmaceuticals Plc Announces Preliminary Safety and Tolerability Results From Its Phase I Clinical Study of MRX-4 in Allergic Rhinitis Patients
9. XTL Biopharmaceuticals Presents Data Regarding its Hepatitis C Virus Small Molecule Program at Hep Dart 2007 - an International Scientific Conference on Viral Hepatitis
10. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
11. Inspiration Biopharmaceuticals Announces Filing of IND for Novel Recombinant Factor IX Product, IB1001, for the Treatment of Hemophilia B
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... market has witnessed robust development with the growth pace keeping ... starter. In 2012, the size of China ... proportion worldwide soaring to 16.3%. It is projected that ... growth rate by around 20% in the upcoming years and ... billion. An integrated membrane industrial system has taken ...
(Date:12/17/2014)... December 17, 2014 Los beneficios ... un alto nivel de gasto en investigación y desarrollo ... (finalizado el 30 de septiembre de 2014) ZEISS aumentó ... millones de euros (año anterior: 4.190 millones de euros) ... Las ganancias (EBIT) crecieron un 14 por ciento, a ...
(Date:12/17/2014)... 17, 2014  Strategic Health Services, Inc. (SHS), a ... announced a strategic agreement with QualCare, Inc., a leading provider ... regional marketplace.  This agreement will further QualCare,s ... wellness solutions QualCare brings to its clients in ... QualCare plans cover more than 800,000 ...
Breaking Medicine Technology:Separation Membranes Market (Company, Country & Application) Research Reports for Global and Chinese Regions 2Separation Membranes Market (Company, Country & Application) Research Reports for Global and Chinese Regions 3ZEISS confirma su posición en un entorno difícil 2Strategic Health Services to collaborate with QualCare on Population Health and Wellness Technology for QualCare Members 2Strategic Health Services to collaborate with QualCare on Population Health and Wellness Technology for QualCare Members 3
(Date:12/19/2014)... HealthDay Reporter THURSDAY, Dec. 18, 2014 ... to high levels of air pollution late in pregnancy may ... suggests. Researchers found that of nearly 1,800 U.S. women ... the most air pollution during pregnancy were twice as likely ... during the third trimester, specifically, showed the strongest correlation to ...
(Date:12/19/2014)... -- Traveling through the same U.S. airport gate, one ... within a four-hour time span, illustrating just how easily ... "The exposures in this report were not prolonged and ... highlighting the fact that measles is highly contagious," wrote ... specialist at the U.S. Centers for Disease Control and ...
(Date:12/19/2014)... HealthDay Reporter THURSDAY, Dec. 18, 2014 (HealthDay ... at least 20 seconds you may be at risk of ... leg may indicate that small strokes or tiny bleeds have ... is high, the investigators reported online Dec. 18 in the ... on one leg, as well as problems walking, should receive ...
(Date:12/17/2014)... 17, 2014 Dr. Myo Nwe is the ... Diet of the Future” and co-founder of the Ace Medical ... Dr. Nwe takes a broad look at the industry of ... under scientific scrutiny. On film and in television shows, however, ... toward the social aspects and played for basic laughs, which ...
(Date:12/17/2014)... 2014 This prestigious award is ... have made outstanding and innovative contributions to the ... of private practice physical therapy by the Private ... , On behalf of Performance Physical Therapy, Michelle ... of Performance accepted the award at the Private ...
Breaking Medicine News(10 mins):Health News:Smog Exposure During Pregnancy Linked to Autism Risk 2Health News:Smog Exposure During Pregnancy Linked to Autism Risk 3Health News:Arriving Now at Gate 42: Measles 2Health News:Arriving Now at Gate 42: Measles 3Health News:Can You Balance on One Leg? You May Have Lower Stroke Risk 2Health News:Obesity Should Not Be a Hollywood Punchline, Weight Loss Doc Says 2Health News:Performance Physical Therapy Awarded with Jayne L. Snyder Private Practice of the Year 2014 2
... , ARLINGTON, Va., Nov. 3 /PRNewswire-USNewswire/ -- "Chiropractic care ... General Becky Halstead (Ret.) at the opening session of the ... CSE 2009, a new educational event offered by the American ... 30 - Nov. 1. , Gen. Halstead served 27 years ...
... National Medical Center and his colleagues from New York University ... the health of morbidly obese adolescents. , The study, ... Surgeons , involved nearly 50 girls and boys ages 14-17. ... mass 2 years after surgery. Android fat has been linked ...
... to predict the popular anti-inflammatory drug, Vioxx would increase the ... discovery that led to the adoption of low dose ... outstanding scientific achievements, Dr. Garret A. FitzGerald has been named ... in Medicine by the Robarts Research Institute at The University ...
... to keep the flu at bay? A strong immune system ... right now can be an important step toward supporting your ... to vitamins, minerals and fiber, fruits and vegetables contain phytonutrients, ... their vibrant colors. These phytonutrients provide a wide ...
... ... , ... -- National Hearing Care has, effective today, completed the acquisition of Bay Audiology. Going forward ... NH C(New Zealand) and Bay Audiology. NHC (New Zealand) will continue to led by James ...
... expert says , TUESDAY, Nov. 3 (HealthDay News) -- Uninsured ... to die from trauma injuries than children with private insurance, ... such as Medicaid or the State Children,s Health Insurance Program, ... private insurance, the study found. , "We have this idea ...
Cached Medicine News:Health News:Retired General Touts Benefits of Chiropractic in the Military 2Health News:Daily dose of color may boost immunity this flu season 2Health News:Trauma Deadlier for Kids Without Insurance 2
... Reference Series 2000 Pipette is a synonym ... compact and robust design, and superior operating ... to operate the measuring stroke and blow-out ... features:Eppendorf "pipette/tip" system ensures utmost accuracy and ...
... The Eppendorf Reference Series 2000 Pipette is ... stroke, a compact and robust design, and ... is used to operate the measuring stroke ... tip. Product features:Eppendorf "pipette/tip" system ensures utmost ...
Inquire...
... Reference Series 2000 Pipette is a synonym ... compact and robust design, and superior operating ... to operate the measuring stroke and blow-out ... features:Eppendorf "pipette/tip" system ensures utmost accuracy and ...
Medicine Products: